AR043959A1 - Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos - Google Patents

Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos

Info

Publication number
AR043959A1
AR043959A1 ARP040101049A ARP040101049A AR043959A1 AR 043959 A1 AR043959 A1 AR 043959A1 AR P040101049 A ARP040101049 A AR P040101049A AR P040101049 A ARP040101049 A AR P040101049A AR 043959 A1 AR043959 A1 AR 043959A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
halogen
formula
aryl
Prior art date
Application number
ARP040101049A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of AR043959A1 publication Critical patent/AR043959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de indolona acetamida que tiene la fórmula (1), o una sal farmacéuticamente aceptables del mismo, o sus formas estereoisómeras, en la cual, R1 es hidrógeno, R2 es hidrógeno o alquilo C1-20, R3 es hidrógeno, alquilo C1-20, cicloalquilo C4-8, cicloalquenilo C5-8, arilo, heterociclo aromático o no aromático, alcoxi C1-20, o un grupo de fórmula -W-R8, R3a es hidrógeno, alquilo C1-20 o un grupo de fórmula (2), o NR3R3a es un grupo de fórmula (3), R4 es hidrógeno, R5 es hidrógeno; nitro; halógeno; azido; ciano; -S-alquilo (C1-4); -SO-alquilo (C1-4); -SO2-alquilo (C1-4); -SONH2; alquilo C1-20 insustituido o sustituido con halógeno; o alcoxi C1-20 insustituido o sustituido con halógeno; R6 es hidrógeno, alquilo C1-20 o halógeno; R7 es hidrógeno, alquilo C1-20 o halógeno; W es alquileno C1-12, -NH- o -NHC(=O)-; X es O, S o NH; Y es O, S, -CR12R13-, -NR14- o -C(=O)-, R8 es arilo o heterociclo; R9, R10, R10a y R11 se seleccionan independientemente de hidrógeno, alquilo C1-4, halógeno, hidroxi o metoxicarbonilo; o R10 y R10a forman juntos un alquileno C3-6, R12 es hidrógeno, alquilo C1-4, halógeno o hidroxi; R13 es hidrógeno, o CR12R13 es dioxolanilo; R14 es arilo, heterociclo o un grupo de fórmula: -V-R15; V es alquileno C1-12; R15 es arilo o heterociclo; m es 1 a 4, n es 0 ó 1; y al menos uno de R5, R6 o R7 es diferente de hidrógeno cuando R2 es hidrógeno; R3 es H o 2,6-disopropil-fenilo; y R3a es H. Composición farmacéutica que lo comprende y uso del mismo para el tratamiento de trastornos neurológicos varios.
ARP040101049A 2003-03-31 2004-03-30 Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos AR043959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03007214 2003-03-31

Publications (1)

Publication Number Publication Date
AR043959A1 true AR043959A1 (es) 2005-08-17

Family

ID=33104041

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101049A AR043959A1 (es) 2003-03-31 2004-03-30 Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos

Country Status (19)

Country Link
US (2) US7645887B2 (es)
EP (1) EP1620399B1 (es)
JP (1) JP2006522041A (es)
KR (1) KR20050119186A (es)
CN (1) CN100364973C (es)
AR (1) AR043959A1 (es)
AT (1) ATE482193T1 (es)
AU (1) AU2004226288A1 (es)
BR (1) BRPI0408863A (es)
CA (1) CA2520568A1 (es)
DE (1) DE602004029245D1 (es)
ES (1) ES2353461T3 (es)
HK (1) HK1089768A1 (es)
MX (1) MXPA05009089A (es)
NO (1) NO20055026L (es)
RU (1) RU2005131317A (es)
TW (1) TW200508197A (es)
WO (1) WO2004087658A1 (es)
ZA (1) ZA200507231B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
WO2005080334A1 (ja) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
DE602005023755D1 (de) * 2004-07-22 2010-11-04 Ucb Pharma Sa Indolonderivate, verfahren zu deren herstellung und deren anwendungen
WO2006118265A1 (ja) 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
CA2610695A1 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
TW200801011A (en) 2006-02-07 2008-01-01 Astrazeneca Ab New compounds II
RU2008144571A (ru) 2006-04-12 2010-05-20 Мерк энд Ко., Инк. (US) Пиридиламидные антагонисты кальциевых каналов т-типа
WO2008133933A1 (en) * 2007-04-26 2008-11-06 Trustees Of Columbia University In The City Of New York Methods, systems, and compositions for treating or ameliorating the effects of a non-congenital hypertonia
US20100222326A1 (en) * 2007-04-27 2010-09-02 Ucb Pharma, S.A. New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
WO2010044878A1 (en) 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
CN107540597A (zh) * 2017-09-22 2018-01-05 苏州大学 N‑乙酰二甲胺基吲哚‑2‑酮衍生物的制备方法
WO2019232083A1 (en) * 2018-05-29 2019-12-05 New York University Compounds and methods for treating bacterial infections
CN114874127B (zh) * 2022-05-23 2023-06-09 中国药科大学 一种二氟羰基化吲哚酮类化合物的制备方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022317B1 (en) * 1979-06-12 1983-09-21 Fujisawa Pharmaceutical Co., Ltd. 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
JPS5697268A (en) * 1979-12-28 1981-08-05 Fujisawa Pharmaceut Co Ltd Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent
SU841264A1 (ru) * 1980-02-20 1995-11-10 Научно-исследовательский институт фармакологии АМН СССР Амид-2-оксо-1-индолинуксусной кислоты, обладающий противосудорожной активностью
DE3413572A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Oxindol-verbindungen zur behandlung der epilepsie
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
DK288287A (da) * 1986-06-09 1987-12-10 Pfizer Heterocycliske forbindelser samt farmaceutiske praeparater til behandling af allergiske eller inflammatoriske tilstande
JPH0195766A (ja) 1987-10-08 1989-04-13 Tamanoisu Kk 無蒸煮アルコール醪からの食酢の製造法
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
JPH07304736A (ja) * 1994-05-10 1995-11-21 Kyowa Hakko Kogyo Co Ltd インドール誘導体
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
FR2738818B1 (fr) * 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
IL127873A0 (en) * 1996-07-08 1999-10-28 Du Pont Pharm Co Amidinoindoles amidinoazoles and analogs thereof as inhibitors of factor xa and of thrombin
JPH1095766A (ja) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
DE602004013563D1 (de) * 2003-03-14 2008-06-19 Merck & Co Inc Rantagonisten
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
DE602005023755D1 (de) * 2004-07-22 2010-11-04 Ucb Pharma Sa Indolonderivate, verfahren zu deren herstellung und deren anwendungen

Also Published As

Publication number Publication date
US20070043038A1 (en) 2007-02-22
EP1620399A1 (en) 2006-02-01
BRPI0408863A (pt) 2006-04-11
CN100364973C (zh) 2008-01-30
MXPA05009089A (es) 2005-11-17
NO20055026L (no) 2005-12-22
JP2006522041A (ja) 2006-09-28
RU2005131317A (ru) 2006-02-27
ZA200507231B (en) 2006-11-29
US20100069375A1 (en) 2010-03-18
TW200508197A (en) 2005-03-01
ES2353461T3 (es) 2011-03-02
US7964593B2 (en) 2011-06-21
DE602004029245D1 (de) 2010-11-04
AU2004226288A1 (en) 2004-10-14
ATE482193T1 (de) 2010-10-15
WO2004087658A1 (en) 2004-10-14
KR20050119186A (ko) 2005-12-20
CA2520568A1 (en) 2004-10-14
HK1089768A1 (en) 2006-12-08
CN1768036A (zh) 2006-05-03
NO20055026D0 (no) 2005-10-28
EP1620399B1 (en) 2010-09-22
US7645887B2 (en) 2010-01-12

Similar Documents

Publication Publication Date Title
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
UY27503A1 (es) Nuevos derivados de piperazina
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AR030243A1 (es) Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral
UY28150A1 (es) Agentes terapeuticos
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
UY29869A1 (es) Compuestos de benzamida
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR057005A1 (es) Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina, una composicion farmaceutica y uso del compuesto para preparar un medicamento
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR065297A1 (es) Formulaciones biodisponibles de compuestos heterociclicos
CO5160242A1 (es) UTILIZACION DE DERIVADOS DE PIRIDAZINO [4,5-b] INDOL-1- ACETAMIDA, PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A LAS ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
AR046874A1 (es) Nuevos metodos
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden

Legal Events

Date Code Title Description
FA Abandonment or withdrawal